TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38565464

Group type: EXPERIMENTAL
Intervention: Ebola vaccine trial participation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Information sharing and communication strategies
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Community involvement in addressing misconceptions
Number of subjects: 70
Study: 38565493

Group type: EXPERIMENTAL
Intervention: Patients with appendicitis
Number of subjects: 53

Group type: COMPARATOR
Intervention: Patients without appendicitis
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Complicated appendicitis
Number of subjects: 53

Group type: COMPARATOR
Intervention: Uncomplicated appendicitis
Number of subjects: 53
Study: 38565753

Group type: EXPERIMENTAL
Intervention: Early removal of silicone oil after 3-4 months (Group A)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Late removal of silicone oil after 6-8 months (Group B)
Number of subjects: 64
Study: 38565810

Group type: EXPERIMENTAL
Intervention: Personalized matching based on therapist effectiveness strengths
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual case assignment (control)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Therapist-level covariates (higher average severity levels, higher proportion of substance misuse or violence problems)
Number of subjects: 206
Study: 38565814

Group type: EXPERIMENTAL
Intervention: Slow-release exenatide (2 mg s.c. once a week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 32
Study: 38565886

Group type: EXPERIMENTAL
Intervention: XELOX plus bevacizumab plus PD1-T cell immunotherapy
Number of subjects: 202

Group type: COMPARATOR
Intervention: XELOX plus bevacizumab (control group)
Number of subjects: 202
Study: 38565993

Group type: EXPERIMENTAL
Intervention: Plasma Kynurenine-to-Tryptophan (K/T) ratio at TB diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma Kynurenine-to-Tryptophan (K/T) ratio after successful TB treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma Kynurenine-to-Tryptophan (K/T) ratio upon treatment failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of K/T ratios with CD4 cell counts in participants with TB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma Kynurenine-to-Tryptophan (K/T) ratio in controls
Number of subjects: 0
Study: 38566034

Group type: EXPERIMENTAL
Intervention: Conventional group (CG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Digital group (DG)
Number of subjects: 36
Study: 38566049

Group type: EXPERIMENTAL
Intervention: Evidence-based nursing practice training programme (EBNPTP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional in-service education
Number of subjects: 80
Study: 38566126

Group type: EXPERIMENTAL
Intervention: Dyssynchronous diaphragm contractions during mechanical ventilation
Number of subjects: 45
Study: 38566164

Group type: EXPERIMENTAL
Intervention: NUC-3373 administered as monotherapy via intravenous infusion on Days 1, 8, 15 and 22 (Part 1) or on Days 1 and 15 (Part 2) of 28-day cycles until disease progression or unacceptable toxicity.
Number of subjects: 59
Study: 38566240

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (exact dosage and duration not specified)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Patients without AKI
Number of subjects: 137
Study: 38566249

Group type: EXPERIMENTAL
Intervention: CTH intervention start-up costs
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CTH intervention hiring and training
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CTH intervention equipment and infrastructure costs
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CTH intervention dashboard creation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CTH intervention hiring and training (median)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CTH intervention purchasing costs (median)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CTH intervention dashboard creation (median)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CTH hiring models
Number of subjects: 34
Study: 38566260

Group type: EXPERIMENTAL
Intervention: Single Leg Squat (SLS) test on the dominant leg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Single Leg Squat (SLS) test on the non-dominant leg
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Hip strength
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Division level (div 2 and div 3)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 254
Study: 38567028

Group type: EXPERIMENTAL
Intervention: Combined measures of triglyceride-glucose index (TyG) and trimethylamine N-oxide (TMAO)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Higher levels of TMAO and TyG
Number of subjects: 274
Study: 38567031

Group type: EXPERIMENTAL
Intervention: Continuous prolonged ECG recording using a patch ECG device (ECG247 Smart Heart Sensor)
Number of subjects: 18
Study: 38567081

Group type: EXPERIMENTAL
Intervention: 0 h hs-cTnT <9 ng/L
Number of subjects: 24973

Group type: COMPARATOR
Intervention: 0 h hs-cTnT <5 ng/L
Number of subjects: 24973

Group type: COMPARATOR
Intervention: 0 h hs-cTnT <6 ng/L
Number of subjects: 24973
Study: 38567102

Group type: EXPERIMENTAL
Intervention: Eprex (epoetin alfa)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Aranesp (darbepoetin alfa)
Number of subjects: 127
Study: 38567196

Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine
Number of subjects: 2040

Group type: COMPARATOR
Intervention: Triple-drug antiretroviral regimens (Control)
Number of subjects: 2040

Group type: EXPERIMENTAL
Intervention: Non-dolutegravir-based cases
Number of subjects: 2040
Study: 38567574

Group type: EXPERIMENTAL
Intervention: Upper limb loading with external weights
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no upper limb loading)
Number of subjects: 0
Study: 38567735

Group type: EXPERIMENTAL
Intervention: Aducanumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38567778

Group type: EXPERIMENTAL
Intervention: Pravibismane
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 38568010

Group type: EXPERIMENTAL
Intervention: NIH Toolbox for Cognition
Number of subjects: 0
Study: 38568107

Group type: EXPERIMENTAL
Intervention: Etidronate treatment
Number of subjects: 7
Study: 38568260

Group type: EXPERIMENTAL
Intervention: Atezolizumab in combination with bosutinib
Number of subjects: 9
Study: 38568396

Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg for 12 weeks
Number of subjects: 0
Study: 38568601

Group type: EXPERIMENTAL
Intervention: Facilitated telemedicine integrated into opioid treatment programs (n=290)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Standard-of-care off-site referral (n=312)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Facilitated telemedicine
Number of subjects: 602

Group type: COMPARATOR
Intervention: Standard-of-care off-site referral
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 602
Study: 38568599

Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization with sorafenib
Number of subjects: 158

Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 158
Study: 38568686

Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1639
Study: 38568690

Group type: EXPERIMENTAL
Intervention: TSPOT
Number of subjects: 22020

Group type: EXPERIMENTAL
Intervention: QFT-GIT
Number of subjects: 22020

Group type: COMPARATOR
Intervention: TST
Number of subjects: 22020

Group type: EXPERIMENTAL
Intervention: Positive TST with QFT-GIT
Number of subjects: 22020

Group type: EXPERIMENTAL
Intervention: Positive TST with TSPOT
Number of subjects: 22020
Study: 38568718

Group type: EXPERIMENTAL
Intervention: Acupuncture with heat therapy in addition to standard care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 100
Study: 38568720

Group type: EXPERIMENTAL
Intervention: Web-based emotion regulation training for sexual function (8-week program)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 60
Study: 38568956

Group type: EXPERIMENTAL
Intervention: Daily rifapentine (600 mg) + isoniazid (300 mg) for 28 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Twice-daily dolutegravir (50 mg) during 1HP treatment
Number of subjects: 32
Study: 38569182

Group type: EXPERIMENTAL
Intervention: Multicomponent hand hygiene intervention including hardware, management and monitoring support, and behavior change.
Number of subjects: 2736

Group type: COMPARATOR
Intervention: Control group receiving the same or improved intervention after endline data collection.
Number of subjects: 2736

Group type: EXPERIMENTAL
Intervention: Multicomponent hand hygiene intervention.
Number of subjects: 2736
Study: 38569352

Group type: EXPERIMENTAL
Intervention: Perampanel (mean maximum dose, 3.5 mg/day for <4 years; 5.3 mg/day for 4-<12 years)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 244
Study: 38569461

Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) identified impairments
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) Vital Sign questionnaire
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA)
Number of subjects: 96
Study: 38569471

Group type: EXPERIMENTAL
Intervention: Metabolically Healthy Obesity (MHO)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Metabolically Unhealthy Obesity (MUO)
Number of subjects: 55
Study: 38569647

Group type: EXPERIMENTAL
Intervention: High-dose quadrivalent influenza vaccine (QIV-HD)
Number of subjects: 33093

Group type: COMPARATOR
Intervention: Standard-dose quadrivalent influenza vaccine (QIV-SD)
Number of subjects: 33093
Study: 38569670

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) therapy as an add-on intervention
Number of subjects: 100
Study: 38569683

Group type: EXPERIMENTAL
Intervention: Remotely delivered perioperative behavioural treatment incorporating principles of behavioural activation, compassion and care coordination, and medication optimisation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Enhanced usual care with mental health-related resources
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Remotely delivered perioperative behavioural treatment
Number of subjects: 300
Study: 38569685

Group type: EXPERIMENTAL
Intervention: Custom CAD/CAM insoles manufactured from direct digital scan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Custom CAD/CAM insoles manufactured from foam box cast
Number of subjects: 0
Study: 38569695

Group type: EXPERIMENTAL
Intervention: Scandinavian Neurotrauma Committee guideline 2016 (SNC16) for management of minor and moderate head trauma
Number of subjects: 0
Study: 38569703

Group type: EXPERIMENTAL
Intervention: Preoperative pancreatic stent placement before enucleation (EN) surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct enucleation (EN) surgery without stent placement
Number of subjects: 0
Study: 38569709

Group type: EXPERIMENTAL
Intervention: PVB+PCIA (30 mL of 0.33% ropivacaine with dexamethasone)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: ESPB+PCIA (40 mL of 0.25% ropivacaine with dexamethasone)
Number of subjects: 102

Group type: COMPARATOR
Intervention: PCIA alone (sufentanil)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: PVB+PCIA
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: ESPB+PCIA
Number of subjects: 102

Group type: COMPARATOR
Intervention: PCIA alone
Number of subjects: 102
Study: 38569758

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care with protocolized diuretic titration
Number of subjects: 240
Study: 38569774

Group type: EXPERIMENTAL
Intervention: Parenteral n-3 polyunsaturated fatty acids supplementation (1.2 g/kg/d)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group (a mix of long-chain and medium-chain fats at 1.0 g/kg/d)
Number of subjects: 268
Study: 38569786

Group type: EXPERIMENTAL
Intervention: 4-week increase in phenylalanine (Phe) intake (1500-3000 mg Phe/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4-week increase in phenylalanine (Phe) intake
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 38569788

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA (2.4 g daily from pregnancy week 24 until 1 week after birth)
Number of subjects: 736
Study: 38569821

Group type: EXPERIMENTAL
Intervention: Remote GDMT titration through the Medly heart failure program
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Remote GDMT titration
Number of subjects: 108
Study: 38569918

Group type: EXPERIMENTAL
Intervention: Longuette chimney stent graft
Number of subjects: 150
Study: 38570031

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 737

Group type: COMPARATOR
Intervention: Not on a ventilator
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of cardiorespiratory events
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Multivariable model including postmenstrual age, cardiorespiratory variables, and ventilator status
Number of subjects: 737
Study: 38570034

Group type: EXPERIMENTAL
Intervention: Cabozantinib at 60 mg/day
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cabozantinib as second-line treatment (n=27)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cabozantinib for patients receiving ICI-based regimens with proven benefits (n=17)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 47

Group type: COMPARATOR
Intervention: Prior therapies (one vs. two)
Number of subjects: 47
Study: 38570057

Group type: EXPERIMENTAL
Intervention: Echotexture biomarkers assessed by ultrasound (US)
Number of subjects: 72
Study: 38570145

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 695

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 695
Study: 38570345

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (8 cycles of 4-min at 80% oxygen saturation)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intermittent hypoxia (compared to older adults)
Number of subjects: 10
Study: 38570629

Group type: EXPERIMENTAL
Intervention: Liver transplant recipients
Number of subjects: 489

Group type: COMPARATOR
Intervention: Controls from the general population
Number of subjects: 489
Study: 38570773

Group type: EXPERIMENTAL
Intervention: Test&Exercise partially supervised programme (n=166)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Otago partially supervised programme (n=158)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Helsana self-administered programme (n=81)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Experimental group (Test&Exercise)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Reference group (Otago)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control group (Helsana)
Number of subjects: 405
Study: 38570800

Group type: EXPERIMENTAL
Intervention: Capillary dysfunction and extracellular vesicles (EVs) characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI performed at 24 hours and 12 months follow-up
Number of subjects: 0
Study: 38570840

Group type: EXPERIMENTAL
Intervention: Post-Acute Home Physiotherapy Program (PAHP)
Number of subjects: 24
Study: 38570855

Group type: EXPERIMENTAL
Intervention: WeChat education group
Number of subjects: 392

Group type: COMPARATOR
Intervention: Regular group (control)
Number of subjects: 392
Study: 38570873

Group type: EXPERIMENTAL
Intervention: 30 mg prednisolone for 5 days
Number of subjects: 314

Group type: COMPARATOR
Intervention: Low-dose colchicine (day 1: 1.5 mg; days 2-5: 1 mg)
Number of subjects: 314
Study: 38570905

Group type: EXPERIMENTAL
Intervention: Kidney Functional Magnetic Resonance Imaging Biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markers of Inflammation
Number of subjects: 0
Study: 38571572

Group type: EXPERIMENTAL
Intervention: MCT ketogenic diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard care reference group
Number of subjects: 12
Study: 38571704

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) using the Tandem shuttle
Number of subjects: 65
Study: 38571816

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Closed-loop acoustic stimulation
Number of subjects: 13
Study: 38572086

Group type: EXPERIMENTAL
Intervention: Stair-climbing and -descending (SCD) for 1 minute after a mixed meal
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Stair-climbing and -descending (SCD) for 3 minutes after a mixed meal
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Stair-climbing and -descending (SCD) for 10 minutes after a mixed meal
Number of subjects: 31

Group type: COMPARATOR
Intervention: Seated control (0 minutes) after a mixed meal
Number of subjects: 31
Study: 38572481

Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol)
Number of subjects: 124
Study: 38572562

Group type: EXPERIMENTAL
Intervention: Pevonedistat, azacitidine, and venetoclax
Number of subjects: 16
Study: 38572639

Group type: EXPERIMENTAL
Intervention: Sotatercept
Number of subjects: 21
Study: 38572643

Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 48
Study: 38572686

Group type: EXPERIMENTAL
Intervention: Dextrain Manipulandum for dexterity assessment (N=36)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Proprioception assessment (N=27)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Box and Block Test
Number of subjects: 42
Study: 38572691

Group type: EXPERIMENTAL
Intervention: Active workstations (standing, walking, or stepper)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Stationary or sitting station (referent)
Number of subjects: 44
Study: 38572955

Group type: EXPERIMENTAL
Intervention: sIL15_TRACK NK cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sIL15_TRACK NK cells with atezolizumab
Number of subjects: 0
Study: 38573065

Group type: EXPERIMENTAL
Intervention: Deep-learning (DL) algorithm for automatic segmentation of renal tumours, kidneys, and perirenal adipose tissue (PRAT) from CT images.
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Model built with features of PRAT for WHO/ISUP grading.
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Model built with combination features of renal tumour, kidney, and PRAT.
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Model built with features solely from tumour lesion.
Number of subjects: 614
Study: 38573083

Group type: EXPERIMENTAL
Intervention: Pre-KT cholecystectomy
Number of subjects: 2295

Group type: COMPARATOR
Intervention: Observation of biliary stones
Number of subjects: 2295

Group type: COMPARATOR
Intervention: Post-KT cholecystectomy
Number of subjects: 2295

Group type: COMPARATOR
Intervention: Risk factors for biliary complications
Number of subjects: 2295

Group type: COMPARATOR
Intervention: Cholecystectomy during follow-up for patients awaiting KT
Number of subjects: 2295
Study: 38573125

Group type: EXPERIMENTAL
Intervention: Coronary MRI
Number of subjects: 74

Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 74
Study: 38573263

Group type: EXPERIMENTAL
Intervention: Seismocardiography using smartphones
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control subjects (non-HF)
Number of subjects: 217
Study: 38573333

Group type: EXPERIMENTAL
Intervention: Autofluorescence-guided hemithyroidectomy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Conventional hemithyroidectomy
Number of subjects: 170
Study: 38573367

Group type: EXPERIMENTAL
Intervention: Engineered TOF-R features
Number of subjects: 524

Group type: COMPARATOR
Intervention: Basic features
Number of subjects: 524
Study: 38573403

Group type: EXPERIMENTAL
Intervention: Additional communication and support by nurse facilitators
Number of subjects: 385

Group type: COMPARATOR
Intervention: Standard communication by ICU clinicians
Number of subjects: 385
Study: 38573466

Group type: EXPERIMENTAL
Intervention: Obesity-centric approach with anti-obesity medications
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual-care approach
Number of subjects: 74
Study: 38573482

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 137
Study: 38573517

Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg monthly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator (Placebo in FRAME, Alendronate 70 mg weekly in ARCH)
Number of subjects: 0
Study: 38573597

Group type: EXPERIMENTAL
Intervention: Radiotherapy dose 51 to 60 Gy
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Radiotherapy dose 50 Gy or lower
Number of subjects: 95

Group type: COMPARATOR
Intervention: Higher radiotherapy dose (70 Gy as reference)
Number of subjects: 95
Study: 38573634

Group type: EXPERIMENTAL
Intervention: Inpatient portal training intervention (touch, in-person [high])
Number of subjects: 2892

Group type: EXPERIMENTAL
Intervention: Inpatient portal functionality intervention (full functionality)
Number of subjects: 2892

Group type: COMPARATOR
Intervention: Built-in video tutorial (low)
Number of subjects: 2892

Group type: COMPARATOR
Intervention: Limited subset of functions (lite)
Number of subjects: 2892
Study: 38573638

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Baseline comparison
Number of subjects: 31

Group type: COMPARATOR
Intervention: Physical Activity
Number of subjects: 31
Study: 38573643

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus durvalumab (FD arm)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus durvalumab and tremelimumab (FDT arm)
Number of subjects: 96
Study: 38573708

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 38573713

Group type: EXPERIMENTAL
Intervention: 6-day insight (Vipassana) mindfulness meditation retreats
Number of subjects: 143

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 143
Study: 38573759

Group type: EXPERIMENTAL
Intervention: Trastuzumab biosimilar Ogivri
Number of subjects: 53

Group type: COMPARATOR
Intervention: Herceptin (historical cohort)
Number of subjects: 53
Study: 38573872

Group type: EXPERIMENTAL
Intervention: Infigratinib 125 mg by mouth once daily for 21 days (28-day cycle) for 2 cycles
Number of subjects: 14